Physician Sentiment on IMFINZI®

🔥🚨@OncoAlert Hot Off the Press BIG NEWS Press Release by @AstraZeneca #ADRIATIC phase 3 trial of #Durvalumab vs #Placebo after concurrent chemoradiotherapy in pts with limited-stage #SmallCell #LungCancer met dual primary endpoints of ⬆️#OS & ⬆️#PFS 👇🏼 https://t.co/DAEapPYsZ7

Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation

@RManochakian

ADRIATIC: relative Durva benefit in pre-specified subgroups 👉PCI: ⬆️ OS overall, but similar Durva benefit 👉Carbo v Cis: Non sig ⬆️ OS benefit 👉BD v OD RT: Comparable OS benefit 🤔 PCI in LS-SCLC better studied in ongoing trials 🤔 Let’s stop using cisplatin #ESMO24 #LCSM

Tom Newsom-Davis

@tnewsomdavis

No! Testing the treatment effect in a subgroup does not carry along with it the covariate adjustment needed, and subgrouping variable BID vs QD probably interacts with an ignored characteristic such as tumor size or nodal extent, and this is grossly misleading! #ESMO24

M. Bolton

@5_utr

Full physician voice list (41)

Physician	Comment (verbatim)	Sentiment	Impressions
Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian	🔥🚨@OncoAlert Hot Off the Press BIG NEWS Press Release by @AstraZeneca #ADRIATIC phase 3 trial of #Durvalumab vs #Placebo after concurrent chemoradiotherapy in pts with limited-stage #SmallCell #LungCancer met dual primary endpoints of ⬆️#…	Positive	28,675
Eric K. Singhi, MD @lungoncdoc	Overheard at Best of #ASCO24 Albuquerque: “Wait. Are you that doctor that dances while giving updates on lung cancer?” Why yes, that’s me 😂	Neutral	24,483
Shankar Siva @_ShankarSiva	📢🚨#ASCO24 plenary @DavidRSpigel - pivotal ADRIATIC ph III trial; adjuvant durvalumab arm after chemoradiotherapy (cCRT) ± PCI in small cell #lungcancer; ⬆️ OS (HR 0.73), median OS 55.9 vs 33.4 for placebo. Grade 3/4 AEs in 24.3% vs 24.2%. …	Positive	15,898
Lecia Sequist, MD, MPH, FASCO @LeciaSequist	Ready backstage for LAURA and ADRIATIC!!! #ASCO24 plenary! ⁦@RamalingamMD⁩ ⁦@DavidRSpigel⁩ ⁦@LaurenByersMD⁩	Positive	12,291
Corinne Faivre-Finn 💙 @finn_corinne	Key slide from the ADRIATIC presentation at #ESMO24 3-yr OS rates: ▶️ BD RT: 65.8% (durva) vs 57.4% (placebo) ▶️ OD RT: 53.1% (durva) vs 43.3% (placebo) ➡️ survival superior with BD RT 📝 CONVERT trial and @myESMO guidelines support adopting…	Neutral	10,571
Dr. Antonio Calles 🫁🚭 @Tony_Calles	🧐 Subgroup analysis in ADRIATIC trial on consolidation durvalumab in LS-SCLC, specifically looking at the role of PCI, cis vs carbo, QD vs. BID radiation regimen. Additionally simultaneous publication on primary analysis @NEJM #ESMO24 #LCS…	Neutral	10,155
Tom Newsom-Davis @tnewsomdavis	ADRIATIC: relative Durva benefit in pre-specified subgroups 👉PCI: ⬆️ OS overall, but similar Durva benefit 👉Carbo v Cis: Non sig ⬆️ OS benefit 👉BD v OD RT: Comparable OS benefit 🤔 PCI in LS-SCLC better studied in ongoing trials 🤔 Let’s st…	Nuanced	9,451
Sanjay Popat @DrSanjayPopat	Dr Senan presents ADRIATIC post hoc prespecified subsets. PCI delivered before randomization. Similar durva benefits for PCI Y/N. Strong durva benefit for carbo but not cis. Strong durva benefit for BID vs OD RT. #ESMO24 @myESMO	Nuanced	6,568
H. Jack West, MD, FASCO @JackWestMD	Agree, practice-changing clear improvement in efficacy, and that doesn't happen often enough in SCLC!! Kudos!!👏🎉	Positive	6,515
Noemi Reguart @NReguart	Second practice changing trial of the day: ADRIATIC Durva consolidation vs plb after cCRT in LS-SCLC. Dual P. endpoints OS/PFS meet (3-y FUP): 24 mo OS gain (median 55.9 vs 33.4, HR 0.73) and 24% reduction in the risk of PFS/death (median 1…	Positive	5,529
Jarushka Naidoo @DrJNaidoo	#ASCO24 Plenary🔥 Ph III ADRIATIC trial of consolidation Durva +/-Treme post cCRT for LS SCLC: - benefit in mOS 55.9 v 33.4m (HR 0.73, p=0.01) & mPFS 16.6 v 9.2m - pneu 10.7% & RT pneu 22.4%* First advance in 30+yrs in LS SCLC @asco @myESM…	Positive	5,439
Hidehito HORINOUCHI @HHorinouchi	🔥#LBA5 ADRIATIC: Durva after CRT in LS-SCLC 🎯Discussant @LaurenByersMD 💯Exemplary way of discussing in plenary session ✅Concise summary of trial ✅Specialist viewpoint on efficacy ✅Future direction #ASCO24 #LCSM @OncoAlert @ASCO	Positive	4,349
Nathan A. Pennell MD, PhD, FASCO @n8pennell	Standing ovations as KM curves revealed interrupt talks for both speakers for LAURA and ADRIATIC trials at #ASCO24 plenary. Totally worth it to be here in person to experience practice changing!	Positive	3,136
Drew Moghanaki @DrewMoghanaki	Udated findings from the ADRIATIC study presented last week by Suresh Senan at #ELCC25 demonstrate that 2 years of durvalumab reduces the risk of brain mets from 12 to 7%. Meanwhile, PCI (not randomized) was associated with a reduction of…	Neutral	2,570
Mariana Brandao @MarianaBrandao0	Interesting data from the ADRIATIC trial on the patterns of recurrence: 🔴 No difference in intrathoracic recurrence btw durva vs placebo arms 🔴 Impressive brain protection, in both PCI treated and untreated pts 🔴 PCI + durva: only 2.8% of b…	Positive	2,342
Dr Amol Akhade @SuyogCancer	ADRIATIC trial . Durvalumab for 2 years consolidation for limited stage SCLC shows OS and PFS benifit. This should be standard of care . @ASCO @brunolarvol @Larvol	Positive	2,330
Salma Jabbour @SalmaJabbour1	ADRIATIC study is the new standard of care for limited stage small cell lung cancer followed by adjuvant durvalumab with improved mOS to 56 mo from 33 mo (placebo) and mPFS of 17 months with durvalumab vs 9 mo (placebo) #ASCO24	Positive	1,971
Bishal Gyawali @oncology_bg	ADRIATIC trial is impressive with this margin of benefit. My only question here is what percentage of control arm patients had crossover. Otherwise, these are great results in SCLC. #ASCO24	Positive	1,951
M. Bolton @5_utr	No! Testing the treatment effect in a subgroup does not carry along with it the covariate adjustment needed, and subgrouping variable BID vs QD probably interacts with an ignored characteristic such as tumor size or nodal extent, and this i…	Negative	1,869
Dr Rishabh Jain @DrRishabhOnco	🚨 ATR inhibition + IO fails to beat chemo in post-IO NSCLC #ELCC26 LATIFY trial: Ceralasertib + Durvalumab vs docetaxel 👇 🧬 Study population • LA/mNSCLC • Progressed after anti-PD-(L)1 ± platinum CT • No actionable mutations 💊 Arms • 🟣 C…	Negative	1,519
Stephen V Liu, MD @StephenVLiu	Dr. @LaurenByersMD with a wonderful discussion of ADRIATIC at #ASCO24 - highlighting a much greater impact on OS with immunotherapy in the limited stage setting than seen in extensive stage.	Positive	1,388
Erika Hamilton, MD @ErikaHamilton9	So proud of @DavidRSpigel for an excellent presentation of transforming results with consolidation durvalumab in small cell #lcsm 🫁 Big win for patients! @SarahCannonDocs	Positive	1,211
A/Prof Tom John @TommyJohn00	Another practice changing study #ADRIATIC presented by @DavidRSpigel #ASCO24. Significant OS benefit for SCLC patients. Another standing ovation. 👏🏾 👏🏾. Pneumonitis not as bad as I would expect.	Positive	1,139
Luis Lara-Mejía @LuisLara_M	In ADRIATIC, durvalumab after cCRT in LE-SCLC delayed time to CNS progression and reduced brain mets — even without PCI. Insightful data shared by Dr. Suresh Senan at #ELCC25. A new horizon for limited-stage SCLC? #SCLC @myESMO	Positive	1,125
Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD	#ADRIATIC - new standard of care in #SCLC, where we have not seen an advance in >2 decades. Truly historic data with use of immunotherapy consolidation #LungPlenary @DavidRSpigel @LaurenByersMD @ASCO #ASCO24 @OncoAlert	Positive	1,109
Dr Riyaz Shah @DrRiyazShah	ADRIATIC. A brilliant presentation by @DavidRSpigel and discussion by @LaurenByersMD. I really reflected on the comment about despite similar HR’s, the absolute extensions are massive in LSvES. @BTOGORG #ASCO24	Positive	1,093
Dipesh Uprety MD FACP @DipeshUpretyMD	#ASCO24 Plenary: ADRIATIC -Pts with limited-stage SCLC post chemo-RT randomized to Durvalumab versus Placebo - Improved PFS and OS with Durvalumab #lcsm @OncoAlert @BTFCancerNews	Positive	1,015
Ben Slotman @bslotman	Suresh Senan presenting exploratory analysis of #Adriatic study in #lungcancer at #ELCC25. Lowest risk of brainmets in #durva arm, esp when pci #radiotherapy is given as well.	Neutral	1,009
Abdulaziz AlJassim 🇵🇸 @DrZ_84	One more Standing Ovation 👏🏼 this time #ADRIATIC results Durvalumab as consolidation treatment for patients with limited-stage SCLC after cCRT. A new standard of care ✅ #ASCOLung #ASCO24 #EndCancer	Positive	989
Shreyas Kalantri, MD @KalantriShreyas	ADRIATIC trial for L-SCLC @ASCO #ASCO24 Consolidation durvalumab - new standard of care for patients who have not progressed on cCRT @HemeOncUofl @HemOncFellows @OncoAlert	Positive	769
Helena Linardou @ElinardouHelena	That unique amazing feeling of the Plenary when practice-changing results are presented… Great day for thoracic oncology! LAURA and ADRIATIC - two immediately practice-changing studies in areas of unmet need! #ASCO24 @myESMO	Positive	660
Sandip Patel MD @PatelOncology	Great discussion of IO in SCLC by @LaurenByersMD @ASCO after presentation of ADRIATIC consolidation durvalumab after chemoXRT in LS-SCLC by @DavidRSpigel #MedIQASCO2024	Positive	631
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ @APassaroMD	The ADRIATIC study might finally highlight a new SoC in limited-stage SCLC after a long (too long) wait. We'll need to see the results to understand the magnitude of its clinical impact, but we're ready to move beyond chemo-only treatment h…	Nuanced	522
F Haroun, MD @Cancer_talks	Durvalumab consolidation for pts with limited-stage small-cell lung ca Spigel #lcsm #asco24 The poor prognosis of SCLC even in limited stg disease translated to an OS benefit in the #ADRIATIC mirroring the CASPIAN results. Different SEA si…	Neutral	500
Alfredo Addeo MD @Alfdoc2	This is IMHO the most impactful study presented at #ASCO24 given the magnitude of benefit, the type and the incidence of the SCLC	Positive	460
Matthias Guckenberger @Mat_Guc	Huge progress after many years of stagnation @DavidRSpigel any details about patients not making it to randomization ?	Positive	455
Aakash Desai, MD, MPH @ADesaiMD	You will need #synergy, for this jab-cross combo I am about to put you through! Plenary #1 2️⃣ #ADRIATIC: Durvalumab as consolidation tx for LS-SCLC. #LBA5 @DavidRSpiegel ➡️ Setting: LS-SCLC ➡️ Endpoint: PFS ➡️ Introducing #IO in #LS-SCL…	Neutral	297
Arianna Marinello, MD @AriMarinel	The time for a practice-changing trial in locally advanced SCLC has come! 🏆 In the ADRIATIC trial: significant OS benefit with durvalumab consolidation versus placebo after CTRT: - 55.9 versus 33.4 months OS at the first interim analysis …	Positive	155
Alex Menter @Alexmenter	Is that SOC arm doing better than we would expect historically? Not sure I have seen updated limited stage KM curves lately and I generally expect worse outcomes. It makes the durva win even more impressive.	Positive	147
Jose G Montoya @JosGilbertoMon1	Time to study adding VGEF to PD-1 (or PDL-1) blockade?	Neutral	129
Isabel Preeshagul @ipreeshagul	#ADRIATIC the first approval in LS-SCLC setting in decades 👏🏽 ⁉️ are there unique characteristics for pts with LS disease? Subtypes? ⁉️should we consider concurrent Durva + CRT vs sequential ? ⁉️how can we better personalize this option…	Positive	106

See full ADRIATIC conference coverage & trial data →

Trial 2 · NCT03732677

What do oncologists think of the NIAGARA trial (IMFINZI®)?

NIAGARA — Muscle-invasive bladder cancer — perioperative (neoadjuvant + adjuvant)

Physicians are broadly favorable, with real nuance on NIAGARA: 40% of 63 verified physician voices positive, 11% nuanced (praising the result while flagging a caveat), 46% neutral, 3% critical.

40%

11%

46%

Positive 40% Nuanced 11% Neutral 46% Critical 3%

Denominator: 63 distinct verified physician voices across 143 oncologist posts, 2024-09-14 to 2026-03-21. Sponsor: AstraZeneca

See full NIAGARA conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT03732677 · FDA — NIAGARA approval (Mar 2025)

FDA approval (Mar 28, 2025): perioperative durvalumab with gemcitabine and cisplatin, then single-agent adjuvant durvalumab after radical cystectomy, for muscle-invasive bladder cancer (based on NIAGARA, NCT03732677).

Physician voices — verbatim

NIAGRA presented #ESMO24 and published today @NEJM – huge accomplishment 1000+ patients enrolled. Exciting results! Some thoughts on applying them to practice...

Elizabeth Plimack MD

@ERPlimackMD

cTDNA in #NIAGARA by @tompowles1 🌀57% (+) at baseline Prognostic before and after cystectomy: 🌀Clearance 13% higher w/ Durva, but Durva arm did better regardless of ctDNA 🌀 (-) not ass w/ pCR, but (+) ass w/ non-pCR & worse EFS Still ❓for benefit of adjuvant #ASCO25

Karine Tawagi MD

@DrKarineTawagi

The benefit of adjuvant durva in patients with a pCR doesn't seem to be an actual benefit...

Michiel Strijbos

@StrijbosMichiel

Full physician voice list (63)

Physician	Comment (verbatim)	Sentiment	Impressions
Elizabeth Plimack MD @ERPlimackMD	NIAGRA presented #ESMO24 and published today @NEJM – huge accomplishment 1000+ patients enrolled. Exciting results! Some thoughts on applying them to practice...	Positive	29,173
Timothée Olivier, MD @Timothee_MD	Post-#ESMO24 #ESMO2024 Edition ! With @VPrasadMDMPH , we review 6 trials: -NIAGARA (periop durva bladder) -AMBASSADOR (adj pembro bladder) -LEAP-012 -SOLARIS (vitD CRC) -CONTACT-02 - and SPLASH in mCRPC	Neutral	24,911
Dr. Antonio Calles 🫁🚭 @Tony_Calles	⭐️ Mind blowing results of immunotherapy across different tumor types presented #ESMO24 now at @NEJM - Melanoma (CM 067) 10 years FU Nivo, Nivo-Ipi. - TNBC (KEYNOTE-522): 5y OS perioperative chemo+pembro - Bladder cancer (NIAGARA): Peri…	Positive	20,062
Oncology Brothers @OncBrothers	One page takeaway from #NIAGARA study that resulted in #durvalumab’s @FDAOncology approval on March 28, 2025 for resectable muscle invasive #BladderCancer #OncTwitter #MedTwitter #gusm @OncoAlert @tompowles1 https://t.co/d1ovIRt4g7	Neutral	15,974
Neeraj Agarwal, MD, FASCO @neerajaiims	Breaking news (practice changing) from @myESMO #ESMO24 👉@tompowles1 presents the 1st results of the ph3 Niagara trial of cisplatin + gemcitabine +\|- durvalumab in MIBC #bladdercancer 👉Significant improvement in DFS (HR 0.68) & OS (HR 0.75) …	Positive	15,107
Tom Powles @tompowles1	NIAGRA: neoadjuvant gem/cis +/- perioperative durvalumab shows significant OS and EFS. #GU25 @MattGalsky now shows the prognostic relevance of pCR. It also showed the durvalumab outperforms the control arm irrespective of pCR. @OncoAlert	Neutral	13,725
Yüksel Ürün @DrYukselUrun	NIAGARA shows that perioperative durvalumab plus neoadjuvant chemotherapy significantly improves event-free survival and overall survival in patients with muscle-invasive bladder cancer compared to neoadjuvant chemotherapy alone. @NEJM @tom…	Neutral	8,160
Roberto Iacovelli @DrIacovelli	Brilliant discussion by @PGrivasMDPhD about NIAGARA trials focused on different roles of neoadj vs. adjuvant part of the study and future perspectives opened by this study. @BladderCancerUS @OncoAlert @GUOncologyNow	Positive	7,521
Toni Choueiri, MD @DrChoueiri	NIAGARA. Chemo +Durva is a NEW SOC in HIGH RISK PERIOP Muscle-Invasive Bladder Cancer #ESMO24. @tompowles1 does it again! Concomitant @NEJM paper!	Positive	7,469
Dr Amol Akhade @SuyogCancer	Excellent slide from @asco #GU25 To compare Niagara vs dose Dense MVAC trials. Neoadjuvant therapy is important in MIBC . @OncoAlert	Positive	6,865
Marta Orozco Belinchon @OrozcoBelinchon	Is this the end of cisplatin in MIBC? With the results from NIAGARA, KEYNOTE-B15/EV-304, and KEYNOTE-905/EV-303, along with the emergence of ctDNA in IMvigor011, it is becoming increasingly difficult to defend it as the sole backbone of pe…	Neutral	6,260
Dra. María Natalia Gandur Quiroga @nataliagandur	📢 @ASCO #GU25 \| Abstract #659 🔬 NIAGARA: Perioperative Durvalumab + NAC improves survival & pCR in MIBC! @tompowles1 @MattGalsky @MichvdHeijde 📊 Key Findings (N=1063, FU: April 2024) ✅ ↓ Risk of metastases/death by 33% (HR 0.67, P<0.001) ✅ …	Neutral	6,225
Petros Grivas @PGrivasMDPhD	Fantastic atmosphere in Barcelona Presidential symposium with practice changing data including NIAGARA trial #bladdercancer @myESMO #ESMO24 #ESMOAmbassadors @OncoAlert @Uromigos @tompowles1 @DrChoueiri @MyriamChalabi @lab_kok @curijoey @KK…	Positive	5,582
Tian Zhang, MD, MHS @TiansterZhang	Masterful discussion from @PGrivasMDPhD -- placing #NIAGARA in context of our #bladdercancer practice -- neoadjuvant and adjuvant OS benefits. Patients are living longer from earlier use of IO agents. Proposes future trial designs. @myESMO …	Positive	5,505
Enrique Grande @drenriquegrande	At #GU25 @MattGalsky is presenting updated data from NIAGARA showing 92% of event free survival rate at 24 months in those participants who achieved a pCR. I am wondering what it would be the EFS if no cystectomy would have performed? 🤔 Doe…	Neutral	4,972
Joshua Meeks @JoshMeeks	Here is the disease-free survival, shown by pCR and non-pCR from Niagara. #AUA2025	Neutral	4,946
Ashish M. Kamat, MD, MBBS @UroDocAsh	Artful discussion by @ERPlimackMD ; here making the case to consider ddMVAC as standard of care in NAC setting, against which all data in perioperative setting, including NIAGRA which used GC, should be evaluated #GU25	Positive	4,471
Vivek Subbiah, MD @VivekSubbiah	⭐️Looking forward to my amazing friend @PGrivasMDPhD discussing the Presidential Session @myESMO #ESMO24 . Stay tuned for his insightful analysis as the discussant on the #NIAGARA trial 👉🏼LBA5 - A randomized phase III trial of neoadjuvant …	Positive	4,461
MikaLion @MichalisLiontos	Best Q&A session ever in #GU25. @MattGalsky @tompowles1 @ERPlimackMD @cnsternberg arguing over best treatment approach in localized Bladder cancer upon presentation of NIAGARA and CM274 updated results!! Excellent discussion from @ERPlimac…	Positive	4,396
Bárbara Melão, MD, PhD @bavilima	Day 2️⃣ @ASCO #GU25 #BladderCancer Impact of pCR on long-term outcomes from NIAGARA @MattGalsky @tompowles1 Peri-operative Durvalumab + NAC ✨Improved EFS & OS ✨reduced the risk of metastases & death ✨pCA linked to better outcomes ‼️ @Mi…	Neutral	3,916
Shilpa Gupta @shilpaonc	#ESMO24 The indomitable & humble @tompowles1 does it again w/ the large practice changing NIAGARA! neoadjuavnt GC durvalumab & adjuvant durva improves EFS & OS compared to GC in MIBC! @montypal @neerajaiims @PGrivasMDPhD @DrRosenbergMSK…	Neutral	3,618
Bertrand Delsuc @BertrandBio	$AZN IMFINZI (durvalumab) perioperative regimen improved EFS and OS across MIBC patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial #ASCOGU25 #GU25 new data incl. DMFS HR 0.…	Neutral	3,605
Andrea Apolo, M.D. @apolo_andrea	UrinaryDNA analysis from NIAGARA shows that baseline and preRC clearance is associated with EFS and durvalumab ⬆️ clearance and was associated with pCR in MIBC #BladderCancer so important to do these biomarker correlative studies. Dr. Van D…	Neutral	3,321
Sabine D. Brookman-May @brookmans76	The right questions addressed by @PGrivasMDPhD after NIAGARA trial presentation: ❓should we proceed with adjuvant treatment in ypT0? ❓Is there a role of ctDNA for adjuvant treatment decisions ❓can pts be cured with systemic therapy #Bladder…	Neutral	3,049
Javier Puente @docjavip	#ESMO24 @tompowles1 has presented another practice changing bladder trial!! periop GC+Durva, meets EFS+OS NIAGARA trial Congrats!!!!!	Positive	3,040
Karine Tawagi MD @DrKarineTawagi	cTDNA in #NIAGARA by @tompowles1 🌀57% (+) at baseline Prognostic before and after cystectomy: 🌀Clearance 13% higher w/ Durva, but Durva arm did better regardless of ctDNA 🌀 (-) not ass w/ pCR, but (+) ass w/ non-pCR & worse EFS Still ❓f…	Nuanced	2,618
Abeid Athman (Omar). @bin_abeid	Professor Petros Grivas @PGrivasMDPhD discussing the NIAGARA trial at the #ESMO2024 presidential symposium. @myESMO @OncoAlert @montypal @DrChoueiri @peters_solange https://t.co/BCvrzT6vHV	Neutral	2,557
Daniel Castellano @cdanicas	🎯🎯 NIAGARA phase III study in MIBC show 3 different important Practice changing! 👇👇 📌 1 - first phase III study with > 1000 pts randomized in neoadjuvant chemo with + OS 📌 2 - the addition of IO therapy (durvalumab) as neoadj and adj settin…	Positive	2,527
Sara Coca Membribes @scocmem	Important biomarker analysis from NIAGARA presented at @ASCO #GU26 @MichvdHeijden Clearance of utDNA appears to be prognostic for EFS (HR 0.24) and negative utDNA status pre RC was associated with higher pCR (72% vs 18%) @OncoAlert	Neutral	1,883
Robert Huddart💙 @robert_huddart	A new standard of care for peri-operative treatment in MiBC? Significant increase in pCR, EFS and most importantly in OS by adding durvalumab to cis gem in NiAGARA trial. #ESMO24 @tompowles1 @PGrivasMDPhD . A breakthrough	Positive	1,644
Renee Maria Saliby @ReneeSaliby	Now moving to NIAGARA w/ @MattGalsky 🔹Perioperative durvalumab + NAC improves EFS & OS in MIBC vs NAC alone. 🔹↓ risk of metastases/death, ↓ bladder cancer mortality (HR 0.69, p=0.008) 🔹pCR linked to better outcomes; benefits seen in pts wi…	Neutral	1,626
Jordan Ciuro, MD @jordanciuro	With new updates in #NIAGARA @ASCO #GU25... 🔎How do these results compare with current context of available treatment in MIBC? How do we adopt this in our clinic on Monday for our patients... NIAGARA vs COXEN vs VESPER 👇 @OncoAlert @GUOn…	Neutral	1,613
Emre Yekedüz @yekeduz_emre	🧬 NIAGARA trial ctDNA (exploratory): Perioperative durvalumab (D) + NAC in cis-eligible MIBC ✅ ctDNA clearance (baseline → pre-RC): • D arm: 41% • Control: 31% 📉 Pre-RC ctDNA+ → 97% non-pCR 📈 EFS benefit with D seen in both ctDNA+& ctDNA- p…	Neutral	1,601
Vinay Prasad MD MPH @VPrasadMDMPH	I know NEJM just wants to amplify their articles, but might it be reasonable to provide critical appraisal? The authors have not even looked at post recurrence data. It is standard to give PD1 in latter lines. Was that the case here? #ESMO…	Nuanced	1,385
Daniel Heng @DrDanielHeng	ctDNA is prognostic and can predict relapse. But durvalumab is still required if you are ctDNA negative. There were still improvements. @tompowles1 is awesome. @oncoalert #ASCO25	Nuanced	1,290
Jason Brown @JasonBrownMDPhD	The awaited Niagara results are here @tompowles1. Perioperative Durvalumab shows clear PFS and OS benefit in MIBC. 💉pCR rate 33% ‼️PFS HR 0.68 👍🏻OS HR 0.75 ❓ Is adjuvant IO needed for all patients?	Neutral	1,156
Michael Serzan, MD @MikeSerzanMD	🗣️Bladder Cancer Oral Abstracts #GU25 Dr @ERPlimackMD discussing Abs658 & Abs659: #CM274 #NIAGARA #CM274 Can ctDNA and PDL1 improve patient selection? #MODERN #NIAGARA Can we ascertain contribution of component parts for NeoAdj vs Adju…	Neutral	1,144
Matt Campbell MD, MS @DocMattCampbell	Fantastic oral abstract session at #GU25 @ERPlimackMD with a masterclass discussion of putting the CM274 and NIAGRA studies into context in both bladder but also looking across the solid tumor spectrum. Great work by @MattGalsky and @MattM…	Positive	795
Brian Rini, MD @brian_rini	discusses the ctDNA data from NIAGARA presented at #ASCO25. ctDNA positivity is distinct from path CR and ctDNA positive patients do poorly	Positive	784
Dr. Tomás Soulé @tomassoule	#GU25 the probability of survival in #MIBC with NIAGARA treatment its more than 90% in those patients with complete response! @MattGalsky we are witnessing a change of era in this disease 🙌🏻 @IntraMedOnco @TresUramigas @OncoAlert @ASCO	Positive	755
Jun Gong @jgong15	NIAGARA cis-eligible #MIBC (cT2-T4aN0/1) 2ndary outcomes ➡️ periop durva + #NAC improved MFS and DSS, pts w/pCR and non-pCR had improved EFS vs control. irAEs mostly low grade and known to durva @asco #GU25 @OncoAlert	Neutral	715
K Takemura @KohjiToncol	Pitfalls in EFS definition in perioperative bladder cancer trials. In NIAGARA, failure to undergo radical cystectomy is counted as an EFS event. However, in KEYNOTE-905 and EV-304, it is not. This difference may affect cross-trial compar…	Nuanced	698
Zach Klaassen @zklaassen_md	⚡️UC Oral Abstract Session⚡️ Additional outcomes and an exploratory analysis of the impact of pCR on long-term outcomes from NIAGARA @MattGalsky @urotoday #GU25 Durva vs Comparison Arm: 📌⬆️EFS (HR 0.68, 95% CI 0.56-0.82) ⬆️ OS (HR 0.75, 9…	Neutral	573
Michiel Strijbos @StrijbosMichiel	The benefit of adjuvant durva in patients with a pCR doesn't seem to be an actual benefit...	Negative	566
Constance Thibault @laconss	Indeed ! Amazing discussion from @ERPlimackMD raising tow major the questions : 1/ Is GemCisDurva a better option than ddMVAC followed by adj Nivo for non responder patients 2/ Do patients with ypT0 after GemCisDurva need adj Durva ?	Positive	526
Sergio Vázquez @OncoLucus	NIAGARA: Probably a new SoC, but we don’t know if it’s better than adjuvant immunotherapy in operable bladder cancer. The pCR is not statistically significant. Fantastic discussion by @PGrivasMDPhD #ESMO24 #bladdecancer	Positive	498
Zayd Tippu @ZaydTippu	Fantastic discussant session from @ERPlimackMD this morning at #GU25 🔍 Role of peri-op IO in MIBC: #CM274 & #NIAGRA 🧬 Biomarker need to optimise stratification and minimise risk of over-treatment ➡️ Emerging risk adapted integrated bi…	Positive	464
Oriol Mirallas MD @DrMirallas	⚡ PRESIDENTIAL Session #ESMO24⚡ NIAGARA: Durva+CisGemx4>IQ->Dura 8 cycles cT2-4N1/0M0 #UC ✅ EFS 67.8 vs 59.8% 2yrs HR 0.68 ✅ OS 82.2vs 75.2% 2yrs HR 0.75 🔬 High PDL1expr 💥 ✔️NEW SoC #MIBC 🗣️ @tompowles1 👏🏼🥊Discussed by @OncoAlert @_S…	Positive	429
Normand Blais, MD @NormandBlais	🇨🇦 is the home of Niagara. Was pleased to take part in this large trial building greater peri-operative treatments for muscle invadive urothelial with my Canadian colleagues. @kalasri3 @DrMichaelOng #ESMO24	Positive	428
Stephanie Berg @bergsa83	What a discussion! By @ERPlimackMD ageee, enrolling on A032103/MODERN using ctDNA stratification is KEY @ALLIANCE_org @SWOG @eaonc @CDNCancerTrials and an NCTN effort!	Neutral	373
Martín Angel @Martin_AngelMD	long-term outcomes from NIAGARA #GU25 @MattGalsky Durva ➕ NAC reduced the risk of developing metastases and death from bladder cancer @IntraMedOnco @Blatam_urology	Neutral	320
Fabio Schutz @FabioSchutz78	Very interesting results. I would assume that perhaps patients with pCR after neoadjuvant therapy would have similar outcome with Durva or Control independently of the neoadjuvant regimen, but that’s not the case. The trend is in favor of a…	Nuanced	309
Álvaro Pinto @dralvaropinto	Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. #GU25	Neutral	223
Yuji Miura @YujiMiura5	I am curious about the similarity of 2 yr OS rate between the non-PCR group in NIAGARA trial and MIBC with prior NAC in CheckMate 274. #GU25	Neutral	206
Kunal Jobanputra MD, DM @KNJobanputra	Crisp summary of the data in MIBC - GC vs ddMVAC and NIAGARA approach. #ASCO #GU25 #ascoGU25	Neutral	180
Anita Turk @anita_turk	Dr Jennifer King with bladder cancer updates: NIAGARA shows perioperative durvalumab improves EFS regardless of pCR/ctDNA status. EV-302 demonstrates 50% maintained response at 24 months among responders. TROPiCS-04 confirms no OS differenc…	Nuanced	159
Matt Galsky @MattGalsky	Trying to reconcile the ctDNA detection rates post-RC from NIAGARA versus IMvigor 010 and other datasets...remember IMvigor 010 only included patients with high risk path features (whereas post RC data in NIAGARA includes all ≥ypT0N0). #Med…	Neutral	141
Scot Niglio MD @ScotNiglio	US FDA approves durvalumab in muscle invasive bladder cancer of off NIAGARA. Congratulations to @tompowles1 and the investigators on the study.	Positive	135
Dillon Cockrell, MD @DCockrellMD	Checkmate 274 update for adjuvant nivolumab also showed improvement in OS. ctDNA trial #MODERN will hopefully help tailor adjuvant treatment. Note that adjuvant nivo is SOC now but was not included in #NIAGARA control arm. Crowded space wit…	Nuanced	134
Maroun Bou Zerdan, MD @MarounBouZerdan	Neoadjuvant gem/cis ± perioperative durvalumab significantly improves OS & EFS. Prognostic value of pCR confirmed, with durvalumab outperforming control regardless of pCR status. NIAGRA via @MattGalsky	Positive	116
Martin ZapataLaguado @zapatalaguadomd	#ASCO25 NIAGARA analysis in miUC using ctDNA, shows a promising opportunity as a predictive tool, showing once again a strong prognosis tool, we need to include these tools to personalise treatment @oncodaily @OncoAlert @achoHematoYOnco @SC…	Positive	59
Dong Nguyen @DongNguyeb	I agree and this study is very fragmentation. The OS is one of many secondary outcome, after multi testing, by chance OS can get statistics significant.	Neutral	55
Laura Bukavina @LauraBukavinaMD	What about ctDNA - patient pre tx ?	Negative	24

See full NIAGARA conference coverage & trial data →

Trial 3 · NCT03800134

What do oncologists think of the AEGEAN trial (IMFINZI®)?

AEGEAN — Resectable NSCLC — perioperative (neoadjuvant + adjuvant)

Physicians are broadly favorable, with real nuance on AEGEAN: 24% of 42 verified physician voices positive, 17% nuanced (praising the result while flagging a caveat), 52% neutral, 7% critical.

24%

17%

52%

Positive 24% Nuanced 17% Neutral 52% Critical 7%

Denominator: 42 distinct verified physician voices across 108 oncologist posts, 2023-04-16 to 2025-06-02. Sponsor: AstraZeneca

See full AEGEAN conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT03800134 · FDA — AEGEAN approval (Aug 2024)

FDA approval (Aug 15, 2024): neoadjuvant durvalumab with platinum-containing chemotherapy, then adjuvant single-agent durvalumab, for resectable NSCLC without EGFR/ALK alterations (based on AEGEAN, NCT03800134).

Physician voices — verbatim

#AACR23 Is #AEGEAN a practice-changing study by @DrRoyHerbstYale? - with similar outcomes to CM816, AEGEAN represents a new option of periop chemo-IO + 1 yr IO - does not replace CM816 - does not address what adj IO adds, therefore a lateral move on practice @OncoAlert #LCSM

Jarushka Naidoo

@DrJNaidoo

#AACR23 #AEGEAN 3yr 63% EFS data (cPR 17%) presented comparable to #CM816 ➡️We shouldn’t do cross-trial comparisons but we can’t help ourselves and wonder: ➡️Is all the benefit of IO seen upfront in the neoadj setting? ➡️What is the optimal duration of IO therapy for maximal

Dr. Estela Rodriguez

@Latinamd

Essentially, parallels KEYNOTE-671 & AEGEAN, now w/nivo. Would have been far more surprised (& disappointed) if it didn't show significant EFS benefit. Another trial that includes adjuvant ICI but can't isolate benefit of post-op; we're left to do cross-trial comp vs CM-816.

H. Jack West, MD

@JackWestMD

Full physician voice list (42)

Physician	Comment (verbatim)	Sentiment	Impressions
Jarushka Naidoo @DrJNaidoo	#AACR23 Is #AEGEAN a practice-changing study by @DrRoyHerbstYale? - with similar outcomes to CM816, AEGEAN represents a new option of periop chemo-IO + 1 yr IO - does not replace CM816 - does not address what adj IO adds, therefore a later…	Positive	61,967
Stephen V Liu, MD @StephenVLiu	Impressive data from #AEGEAN at #AACR23 from Dr. John Heymach and colleagues. This is the first of several phase III peri-operative IO studies in resectable NSCLC combining neoadjuvant chemo-immunotherapy followed by adjuvant immunotherapy.	Positive	49,894
Nathan A. Pennell MD, PhD, FASCO @n8pennell	Based on the CM 816, Aegean and now KN 671, for stage 2/3 resectable NSCLC with no genomic alterations, do you give: #ASCO23	Neutral	32,093
Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian	🔥🚨@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO23. “Results of #AEGEAN trial of #Perioperative #Durvalumab (or #placebo) + neoadjuvant chemo in #Patients with respectable stage II-IIIB…	Positive	28,836
Oncology Brothers @OncBrothers	#CM816 3yr update was recently presented at #ELCC23 (OS: 0.67 and EFS 57% at 3yrs/65% at 2yrs) and today, #AEGEAN data was presented at #AACR23. How much is adjuvant durva adding here? Unfortunately, we are left with cross trial comparisons…	Neutral	24,902
Paolo Tarantino @PTarantinoMD	Three phase 3 trials of neoadjuvant IO for NSCLC with survival data. 2-year EFS was: - 63.8% with neoadjuvant only nivo (CM816, 4 cycles of IO) - 62.4% with neoadjuvant + adjuvant pembro (KN671, 17 cycles of IO) - 63.3% with neoadjuvant + …	Neutral	23,080
Drew Moghanaki 🐕 @DrewMoghanaki	Once again, many participants (22%) who were started on systemic therapy didn't make it to surgery. By comparison: CM816 = 20%, AEGEAN = 19%. Are any of these people being harmed by delaying concurrent chemoRT with the hopes that they'll ma…	Neutral	19,712
Noemi Reguart @NReguart	AEGEAN phase 3 trial with perioperative Durvalumab+ neoadj chemo presented by Dr. Heymach at #AACR23 👉 49% N2+, EFS NR vs 25.9 mo (HR 0.68, p 0.0039), 24-mo EFS 63% vs 52% (median FUP 11.7 mo, 31.9% maturity), pCR rate 17% vs 4%, MPR 33% vs…	Positive	16,820
Lei Deng, MD (He/Him) @LeiDeng3	While debating on Adj IO after Neoadj ChemoIO in NSCLC w/ #CM816, #AEGEAN, #KN671 data, the ❓ is probably not a simple ✅or❎. Rather, the ❓probably should start w/ Who. Our Periop Gastric Chemo data suggest Preop Response may inform Postop T…	Neutral	15,841
H. Jack West, MD @JackWestMD	Essentially, parallels KEYNOTE-671 & AEGEAN, now w/nivo. Would have been far more surprised (& disappointed) if it didn't show significant EFS benefit. Another trial that includes adjuvant ICI but can't isolate benefit of post-op; we're l…	Negative	13,293
Hidehito HORINOUCHI @HHorinouchi	🔥AEGEAN: Association of ctDNA clearance and pathologic response 🎙️@MartinReck2 🎯Earlier ctDNA CL was associated with higher likelihood of pCR and MPR. ✅Phase III ✅Primary: EFS ✅Stage II–IIIB(N2) NSCLC ✅NCT03800134 #ESMO23 #LCSM @myESMO @onc…	Positive	12,801
Timothée Olivier, MD @Timothee_MD	18 anti-cancer drugs approved in the neo/adjuvant setting since 2018. With @VPrasadMDMPH & @AlysonHaslam, we R keeping a close eye on those. update data with AEGEAN: https://t.co/ehtahZMTnf 7 just in lung cancer !👇 @Alfdoc2 @peters_sola…	Neutral	11,208
Dr. Estela Rodriguez @Latinamd	#AACR23 #AEGEAN 3yr 63% EFS data (cPR 17%) presented comparable to #CM816 ➡️We shouldn’t do cross-trial comparisons but we can’t help ourselves and wonder: ➡️Is all the benefit of IO seen upfront in the neoadj setting? ➡️What is the opt…	Nuanced	10,392
Dipesh Uprety MD FACP @DipeshUpretyMD	AEGEAN: a phase III trial w/ pts w/ resectable stage IIA-IIIB NSCLC without EGFR/ALK-->randomized to neoadjuvant chemo (X4 cycles )± durva followed by adj placebo vs durva for 1 yr--> ↑ EFS with Durva #AACR23 @OncoAlert #LCSM	Neutral	9,494
Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD	The field of Thoracic Oncology is moving faster than we can keep up! Another @NEJM article, this time on AEGEAN- first reported @AACR, now published, with full results of peri-operative Durvalumab in resectable #NSCLC @ESMO_Open #ESMO23 h…	Positive	8,583
Dr Riyaz Shah @DrRiyazShah	KEYNOTE671: Double blind RCT; only cisplatin regimens 🙁; 3/4 completed 4cycles; About 20% never operated☹️; 40% completed 1y; pneumonectomy rate same; 2yEFS landmark 62% seems same as Aegean and CM816. Makes me doubt the post op IO adds muc…	Neutral	8,130
Giannis Mountzios @g_mountzios	#AACR23 Great presentation of #AEGEAN but more Qx arise-Some food for thought compared to #CM816: 1/5 👉Histology and sex NOT a strata factor in AEGEAN 👉Pts had 4 cycles of neoadj chemo,might explain in part the slightly better perf. of PBO …	Nuanced	5,951
Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ @APassaroMD	🚨AEGEAN just out #AACR23 ◾️pCR: 17.2% vs 4.3% ◾️mEFS: NR vs 25.9m (HR 0.68),mF-up 11.7 m ◾️Same% in both arms underwent surgery ❗️Be careful w/ cross-trial comparisons❗️ For now, these results confirm chemo+ICI as the effective backbone in …	Neutral	3,963
F Haroun, MD @Cancer_talks	#Keynote671 Presented at #ASCO23 by Dr. Mark Awad #LCSM EFS, trend toward OS benefit of this neoadj/adj chemo/io strategy vs neoadj chemo alone is impressive- pCR rates of 18% vs 4% HR 0.42 PDL1>50%, HR 0.51 1-49% and HR0.77 in PDL1 neg (…	Positive	3,795
Dr. Antonio Calles 🫁🚭 @Tony_Calles	🧬 cDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase Ill AEGEAN trial @MartinReck2 Another @NEJM #ESMO23 #LCSM	Neutral	3,497
d.planchard @dplanchard	AEGEAN impressive pCR with durvalumab 4 cycles + chemotherapy and promising EFS. Contribution of adjuvant durvalumab remains unclear (vs CM816) : waiting more mature results with OS … ? #AACR23	Positive	3,208
Bartomeu Massuti @bmassutis	AEGEAN trial with Durvalumab confirms improvement of pCR and EFS for perioperative chemoimmunotherapy in resectable NSCLC with similar impact that Checkmate 816 and NADIM 2 performed by @gecp_org @MARIANOPROVENCI #AACR23 @OncoAlert	Neutral	3,027
Julien Mazieres @JulienMazieres	Interesting approach using ctDNA clearance as a surrogate marker of efficacy of neoadjuvant durvalumab chemo (AEGEAN trial in stage 2/3 NSCLC) @MartinReck2 #ESMO23 @OncoAlert	Neutral	2,109
Shruti Patel, MD @ShrutiPatelMD	16/24 #TumorBoardTuesday #LungCancer #NSCLC 👩🏽‍🏫Mini tweetorial 12👩🏽‍🏫 ✨AEGEAN 🔹PHASE III Stage IIA-IIIB 💉arm: 4 rounds of durvalumab + platinum-doublet ➡️ ✂️ ➡️ adjuvant durvalumab ⭕️arm: 4 rounds of placebo + platinum-doublet ➡️ ✂️ ➡️ pl…	Neutral	1,851
Tom Newsom-Davis @tnewsomdavis	AEGEAN: Although numbers small, EGFRmut patients derive less benefit from neoadjuvant chemoIO ❗️EFS HR = 0.86 ❗️Difference in pCR = 3.8% We should test EGFR before embarking on neoadjuvant strategy. Adjuvant Osimertinib a better option if…	Nuanced	1,751
David Gandara @drgandara	⁦@DrRoyHerbstYale⁩ giving a “Tour de Force” discussion of AEGEAN neoadjuvant-adjuvant trial in early stage NSCLC at AACR23. Concludes that this regimen is “a” new SOC but not yet “the” SOC, given other positive trials in this space. Awaitin…	Nuanced	1,252
Jeff Ryckman @jryckman3	Yes, but the issue is, we don’t know if NA(C)-ICI—> surgery or NA(C)-ICI—> CCRT is superior for more advanced patients (e.g., multi-station N2, endobronchial involvement, central tumors… or patients req more advanced resections such as slee…	Nuanced	1,240
Jennifer A. Marks, MD @jennifermarksmd	Dr. @MartinReck2 presents an exploratory analyses from AEGEAN of high-risk pts who may have reduced benefit with IO. Potential association here of KMT2C and KEAP1 mt for MRD @asco #ASCO25 #lcsm #lcam	Neutral	1,172
Balazs Halmos @BalazsHalmosMD	Do we have any MRD (minimal residual doubt) that MRD assays will make a major impact in risk stratification in periop/peri-xrt patient management? The plot thickens as to their clinical value/utility!	Neutral	1,045
Bijoy Telivala @BijoyTelivala	Biggest problem in community and many academic centers Trials included " resectable pts " These days so many unresectable pts offered neoadj- than cant get surgery or get bad surgery and than get chemo/xrt- pacific protocol When we abandom …	Negative	801
Marcelo Corassa, MD. @MarceloCorassa	Is ctDNA ready for prime time in resectable NSCLC? Or it is just a reflex of a poor response to neoadjuvant chemo-IO and a dismal molecular profile? High risk patients are high risk patients despite of MRD. Great presentation by Dr. Reck #A…	Neutral	661
David O Reilly @DavidOReilly2	ESMO Lung Mini-orals Checkmate816 - Improved OS in in PDL1 positive group (HR O.43) Rationale 315 - pCR of 40% AEGEAN - Non clearance of ctDNA predictive of patients unlikely to have pCR IMPower010 - High TGFB CAF associated with poor DFS …	Positive	639
Jaskirat Randhawa @Jaskirat__SR	Neoadjuvant Chemotherapy and #Immunotherapy in #NSCLC – Unveiling the Treatment Landscape #ESMO23 #lungcancer - important results from checkmate 816, Aegean trial, checkmate 77T, keynote 671 https://t.co/u8kLoyNJFO	Neutral	568
Mike Masciadrelli @mgmasciadrelli	“We have to do better. We have to bring our immunotherapies earlier” @DrRoyHerbstYale a discussant this afternoon on the phase III AEGEAN clinical trial at the @AACR annual meeting #AACR23	Neutral	525
Chul Kim @chulkimMD	In #AEGEAN, majority of patients with MRD+ NSCLC had persistent ctDNA during neoadjuvant therapy and experienced rapid relapse after surgery. KMT2C and KEAP1 mutations associated with MRD status. Can MRD assays identify pts who could benef…	Positive	497
A/Prof Tim Clay @drtclay	#WCLC2023 AEGEAN periop durvalumab - EGFR mutation subgroup Minimal benefit for durvalumab in this population —> test actionable oncogenes before neoadjuvant therapy in NSCLC is critical @EGFRResisters	Negative	429
Katsuaki Maehara 🇯🇵 @KatsuakiMaehara	AEGEAN : Japanese subgroup analysis Japanese analysis was presented at the Japan Lung Cancer Society meeting. @t_mitsudomi ● Baseline characteristics and planned Tx (mITT) Many Japanese ・male, ECOG-PS, stage Ⅱ, TC≥50%	Neutral	263
Andrew Hong @hongdrew	very nice roundup as always! Thanks for sharing -- you may have this already, but early-stage NSCLC (CM-816, KN-091, AEGEAN... ASCO guidelines updated recently) https://t.co/TSMsJHknJ8	Nuanced	228
David Henry @davidhenrymd	#Neoadjuvant #Durvalumab does not affect surgical outcomes in #NSCLC: Study 👉https://t.co/Af7Z9xjL3g @MDedgeHemOnc #AEGEAN	Neutral	127
Ido Wolf @IdoWolf5	Financial toxicity Time toxicity No proven benefit over neoadjuvant nivo chemo.	Nuanced	124
Veli Bakalov, MD @HemeOncBuddy	AEGEAN trial Heymach JV et al, N Engl J Med, 2023, PMID: 37870974 https://t.co/UwuvHNVU2Z Background: randomized clinical trial included 802 patients diagnosed with resectable stage II to IIIB (N2) non–small cell lung cancer (NSCLC), exclu…	Neutral	81
Anis Toumeh, MD @AnisToumeh	Important update. I am very interested in looking at other peri-operative trials’ (AEGEAN, NEOTORCH) long term outcomes. #ASCO23 #lungcancer #Immunotherapy	Neutral	52

See full AEGEAN conference coverage & trial data →

Trial 4 · NCT04592913

What do oncologists think of the MATTERHORN trial (IMFINZI®)?

MATTERHORN — Resectable gastric/GEJ adenocarcinoma — perioperative FLOT

Physicians are broadly favorable, with real nuance on MATTERHORN: 51% of 45 verified physician voices positive, 11% nuanced (praising the result while flagging a caveat), 33% neutral, 5% critical.

51%

11%

33%

Positive 51% Nuanced 11% Neutral 33% Critical 5%

Denominator: 45 distinct verified physician voices across 95 oncologist posts, 2024-06-02 to 2026-05-13. Sponsor: AstraZeneca

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Primary sources: ClinicalTrials.gov · NCT04592913 · FDA — MATTERHORN approval (Nov 2025)

FDA approval (Nov 25, 2025): perioperative durvalumab with FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel), then single-agent durvalumab, for resectable gastric/GEJ adenocarcinoma (based on MATTERHORN, NCT04592913).

Physician voices — verbatim

MATTERHORN is positive for EFS! Full data awaited. Looks like a potential practice changer. Will FLOT+Durva be new SOC? https://t.co/yHKFLACZlG

Udhayvir Grewal

@UGrewalMD

🔥 Chemo-IO climbs the MATTERHORN! Durvalumab + FLOT ⛰️ lifts peri-operative gastric/GEJ cancer outcomes at #ESMO25 ✅ OS HR 0.78 (p = 0.021) ✅ Higher pCR & EFS gains across PD-L1 +, node-positive & diffuse subgroups 💪 Median OS NR in both arms — but curves clearly part https://t.co/D5pyoDb8oT

Dr Rishabh Jain

@DrRishabhOnco

This is why I think press releases w/o numbers are problematic... Framing MATTERHORN as showing “clinically meaningful” benefit kinda prevents one from forming an independent opinion of results (10% 2 yr EFS, OS trending) when #s do come out Look forward to presentation #ASCO25

Dr. Nina Niu Sanford

@NiuSanford

Full physician voice list (45)

Physician	Comment (verbatim)	Sentiment	Impressions
Udhayvir Grewal @UGrewalMD	MATTERHORN is positive for EFS! Full data awaited. Looks like a potential practice changer. Will FLOT+Durva be new SOC? https://t.co/yHKFLACZlG	Positive	30,901
Nicholas Hornstein @GIMedOnc	Holy smokes, MATTERHORN hits OS! 🏔️🔥 We’ve been waiting for this one. After FLOT became standard for resectable gastric and GEJ adenocarcinoma, everyone wondered if adding immunotherapy could move the bar. Earlier this year, MATTERHORN sho…	Positive	28,048
Oncology Brothers @OncBrothers	This is amazing and will likely become the new SoC… but… how I wish there was that third arm to tell us how much benefit there is from postOP IO (same struggle in TNBC (KN522👇), NSCLC (AEGEAN 👇), soon in bladder cancer (NIAGARA 👇) and now M…	Positive	26,669
Dr Amol Akhade @SuyogCancer	Top 10 GI Trials – ASCO 2025 The biggest GI breakthroughs you must track this year! 🧬 ATOMIC – Atezolizumab + FOLFOX in stage III MSI-H colon 🛡️ MATTERHORN – Durvalumab + FLOT in gastric/GEJ 🧪 DYNAMIC-III – ctDNA-guided chemo in colon 💉…	Neutral	26,479
Arndt Vogel @ArndtVogel	MATTERHORN: Phase III study of durvalumab + FLOT in resectable G / GEJ adenocarcinoma #ESMO25 #ESMOAmbassadors 👉 pCR: 16%, MPR: 26%, any: 87% 👉 OS: HR: 0.78; 36-mo OS: 68 vs 61% 🧐OS improved independent of TAP, better in responders > new SO…	Positive	15,057
Sharlene Gill, MD, MPH, MBA, FASCO @GillSharlene	#ASCO25 @ASCO 4 weeks away and looks like it is going to be a practice-changing #ASCO25 for #GIcancers👍 👇my top picks for key abstracts to watch for🌟 ➡️Two GI plenary sessions🏅 MATTERHORN #STCsm @YJanjigianMD ATOMIC #dMMR #CRCsm @FASinicr…	Positive	12,227
Yakup Ergün @dr_yakupergun	MATTERHORN: Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer https://t.co/GYoI0ebmnY	Neutral	11,356
Mario Balsa @MarioBalsaMD	🧵 Non-metastatic gastroesophageal adenocarcinoma – shifting landscape at #ESMOGI25 ▪️FLOT > CROSS for OS ▪️↓ distant relapses with FLOT ▪️Peri-op IO rising: MIGHTY MATTERHORN! ▪️RT & adjuvant IO have lost ground 🧗‍♂️Climbing towards a new…	Neutral	10,204
Kohei shitara @KoheiShitara	Mattehorn study showed EFS improvement and strong OS trend with FLOT+duravalumab. Great news to establish the global standard for fit patients with locally advanced gastric/GEJ cancer. Looking forward to the detail.@OncoAlert @oncodaily	Positive	4,781
Vivek Subbiah, MD @VivekSubbiah	4/ Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer #ASCO25 @ASCO	Neutral	4,711
Krishan Jethwa @KrishanJethwa	KN-585, MATTERHORN, DANTE are exploring peri-operative chemotherapy (Cis/FU or FLOT) +/- ICI (Pembro/Durva/Atezo) for resectable, LA Gastric/GEJ adenocarcinoma, respectively KN-585: 🟰 OS; ⬆️ EFS MATTERHORN/DANTE: ⬆️ pCR, EFS maturing At p…	Neutral	3,480
Dr Rishabh Jain @DrRishabhOnco	🔥 Chemo-IO climbs the MATTERHORN! Durvalumab + FLOT ⛰️ lifts peri-operative gastric/GEJ cancer outcomes at #ESMO25 ✅ OS HR 0.78 (p = 0.021) ✅ Higher pCR & EFS gains across PD-L1 +, node-positive & diffuse subgroups 💪 Median OS NR in both…	Nuanced	3,120
Dr. Nina Niu Sanford @NiuSanford	This is why I think press releases w/o numbers are problematic... Framing MATTERHORN as showing “clinically meaningful” benefit kinda prevents one from forming an independent opinion of results (10% 2 yr EFS, OS trending) when #s do come o…	Negative	2,623
Erman Akkus @Erman_Akkus	📢MATTERHORN Upper GI proffered #ESMO25 ✅Significant OS D + FLOT vs FLOT HR: 0.78; (95% CI: 0.63–0.96) p=0.021 🧐❓PD-L1 TAP <1%: (HR, 0.79; 95% CI: 0.41–1.50) #cancer #oncology #MedX #GI #gastrointestinal @OncoAlert @brunolarvol @OncBrothe…	Neutral	2,384
Tim Brown, MD MSCE @TimothyJBrownMD	I had a great time meeting with @NiuSanford @KlempnerSam discussing our takes on MATTERHORN and SANO and their impact on management of upper GI cancers today	Neutral	2,115
Benlazar S M A @smbenlazar	ROXADUSTAT IMPROVES TRANSFUSION INDEPENDENCE IN LR-MDS PATIENTS WITH ANEMIA AND HIGH TRANSFUSION BURDEN AND IN RING SIDEROBLAST POSITIVE AND NEGATIVE DISEASE: POST-HOC ANALYSIS OF MATTERHORN STUDY.. by Amer M. Zeidan ,EHA Library; https…	Positive	1,790
Ryan Huey, MD, MS @ryanhuey	Dr. Klempner shows the landscape of resectable gastric cancer treatment and suggests MATTERHORN should change practice TODAY. #ASCO25	Positive	1,725
Nieves Martinez Lago MD PhD @DraMartinezLago	📣Great news for patients with resectable gastric tumors! MATTERHORN trial has met its primary endpoint. 💪 Positive for EFS. ⏳ OS - Awaiting final analysis. Read more here: https://t.co/ptcoxIf2gM @OncoAlert @GrupoTTD	Positive	1,620
Dr Joseph McCollom DO @realbowtiedoc	Dr @KlempnerSam summarize the importance of #MATTERHORN for #esocsm and #stmcsm including comparisons to KN-585 in the spectrum of perioperative therapy during the #plenary here at #ASCO25 @YJanjigianMD @yekeduz_emre @DRBakaloudiMD @Andr…	Neutral	1,203
M. Bolton @5_utr	❗️ MATTERHORN: Ph3 RCT periop FLOT +/- durva for resectable G/GE adenocarcinoma Overall survival: HR 0.78 (0.63–0.96) #ESMO25	Positive	1,128
Pashtoon Kasi MD, MS @pashtoonkasi	🗣️Great discussion by @KlempnerSam about putting the data 📊 into context. 🙏🏽 for also coining D-FLOT. @YJanjigianMD ✅MATTERHORN ⬆️📈. Cool 🆒 AI 🤖 use of overlaying the curves 📉from the original study 🇩🇪. #ASCO25 @OncoAlert	Neutral	956
Eduardo Terán @EduardoTB94	Matterhorn ph3 trial POSITIVE for EFS in locally-LA EGC 🤩 Will it translate into increased OS? Maybe for PD-L1+ pts? 🆕 SOC? Feasible approval? How will it impact subsequent lines? Lots of questions on the table 🙇🏼 #UpperGI is 🔥 @VHIO @Gru…	Positive	943
Juan OConnor @Juanmaoconnor	Excellent update by @RadkaObermanno1. MATTERHORNclearly in the lead, but SKYCRAPER 07, definitely still in play for the squamous tumors! #ESMO25 #myESMO #Immunotherapy 👏	Nuanced	838
Heber Reyes, MD @EoHeb	So, after Plenary Session #ASCO25, current practice did change? ATOMIC: yes, but consider neoAdj IO if possible NIVOSTOP: yes, but KN689 could be used too SERENA-6: yes, but I hope for accesible testin' MATTERHORN: maybe, I'd wait for OS d…	Nuanced	761
Mark Lewis, MD, FASCO @marklewismd	We talk a lot about practice-changing data affecting the 1st post-ASCO clinic but there’s also such rich dialogue at the tumor boards meeting after #ASCO25 — so meaningful to contextualize findings in multidisciplinary fashion especially pe…	Positive	710
Oscar Tahuahua @OscarTahuahua	Durva may not be the best drug, but they have a fantastic team that designs clinical trials. They've achieved truly impressive results. Without the third arm, overtreatment is likely	Positive	677
Duilio Rocha @duiliorocha_onc	Advances in periop treatment beautifully shown by Dr. Sylvie Lorenzen-Munich. 2-y OS 41% in Magic control arm vs 75% in D-FLOT MATTERHORN arm. 🏔️We´re climbing the mountain. #ESMO25 @OncoAlert	Positive	578
Dr. Estela Rodriguez @Latinamd	Great overview of #ASCO25 GI Cancer Highlights by @DrBonillaOnc #ASCODirect Puerto Rico ✅ #CHALLENGE ✅ #ATOMIC ✅ #BREAKWATER ✅ #MATTERHORN ✅ #DESTINYGastric04 @TotalHealthConf	Positive	521
Santhosh Ambika @RenoHemonc	Pre ASCO prediction coming true as expected	Positive	496
Daniel Acosta Eyzaguirre @DanielAcostaEy1	🔥Good news! More options coming for patients with resectable gastroesophageal tumors! #gastricCancer @GrupoTTD @VHIO 📢MATTERHORN trial positive for its primary outcome. 💪Positive for EFS! ⏳OS - Wait for final analysis.	Positive	470
Arturo LoAIza-Bonilla, MD MSEd @DrBonillaOnc	Breaking Down MATTERHORN: Durvalumab Plus FLOT in Gastric Cancer #ASCO25 ⁦@TargetedOnc⁩ ⁦@mystlukes⁩ ⁦@MassiveBio⁩	Neutral	389
Tsung-Che Wu @TsungCheWu	MATTERHORN trial (perioperative FLOT ± durvalumab in gastric cancer) positive for EFS! Looking forward to seeing the survival curves—this could accelerate the shift in East Asia from traditional D2 + adjuvant therapy to a perioperative appr…	Positive	343
Richard Dunne, MD @DrR_DUNNE	Matterhorn shows statistically significant improvement in event free survival when adding Durva (immunotherapy) to standard chemo in Resectable Gastric and GEJ Cancer (HR 0.71) #Asco25	Positive	311
Suneel Kamath MD @SKamath_MD	MATTERHORN is out! 🔹️Perioperative durvalumab+FLOT significantly improves 2-year event-free survival (67.4% vs. 58.5%). 🔹️OS not mature. 🔹️Adverse event rates similar. #ASCO25 https://t.co/txIRjAH8H3	Nuanced	294
Daisuke Kotani, MD, Ph.D 小谷大輔 @DaisukeKotani	🚩LBA81: Final OS from MATTERHORN trial ✅Significant OS improvement with Durvalumab + FLOT vs. placebo + FLOT, HR 0.78, p=0.021 ✅Consistent efficacy regardless of TAP score 💡D + FLOT is new SOC for localized GC/GEJ adenocarcinoma #ESMO25 @m…	Positive	250
Nirmal Raut @oncologician	#ESMO25 - Matterhorn trial has challenged the current SOC . It establishes Durvalumab + FLOT as peri operative treatment for StG II -IV A Esophageal and gastro esophageal cancer @Amolpatel_dr @roxboxfix @Geeky_Foodie @DrRishabhOnco @UmutDis…	Positive	240
Rutika Mehta @rutikamehtaMD	Wonder how to best treat locally advanced #GECs? Watch @mdmanishshah and me discuss #MATTERHORN and #CM577 from #ASCO25 👇https://t.co/xGjtu9qdBq via @vumedi @WCMGIcancer	Neutral	224
Yuan James Rao @yuanjamesrao	In retrospective data, dCRT (+/- induction) for esophageal adenoca can result in cCR of 80 percent and 2 year LC of about 50 percent, and OS of 50-60 percent. Slightly worse than MATTERHORN but not that far off. Also mostly were inoperabl…	Nuanced	211
Kunal Jobanputra MD, DM @KNJobanputra	What about post-progression therapy in the control arm? No one dared to question the mountain 🙃 #ASCO2025	Negative	197
Thierry Alcindor, MD, MSc @Thalcin	Agree with all comments about relationship of PD-L1 status and pCR with outcomes, especially OS. MMR status would also be interesting to look at.	Neutral	96
Bijoy Telivala @BijoyTelivala	PD L score less than 1 % - was just 10 % of population In reality it takes time to come back and diff pathology labs will use diff tests which also have variance I will start in all and if score is low , discuss pro and cons and let pt de…	Neutral	95
Anita Turk @anita_turk	Dr. Shadia Jalal discusses MATTERHORN: Adding durvalumab to FLOT in resectable HER2-negative gastric/GEJ cancer improves pCR and EFS. #ASCO25 @IUCancerCenter	Neutral	95
Namrata (Neena) Vijayvergia MD @NVijayvergiaMD	That’s how nccn recommends it now	Neutral	90
Michael KC Lee @MichaelKuanChi1	No more debate. Improved OS really ask for new standard of care and now hope we get this through TGA quickly for patients of Australia	Positive	78
Corey Speers @cwspeers	📌 MATTERHORN Trial (Gastric Cancer) 🔹 Durvalumab (Imfinzi) + perioperative FLOT chemotherapy 🔹 29% improvement in event-free survival 🍽️ Significant advancement for gastric and gastroesophageal junction cancers!	Positive	39

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Trial 5 · NCT02125461

What do oncologists think of the PACIFIC trial (IMFINZI®)?

PACIFIC — Unresectable Stage III NSCLC — consolidation after chemoradiation

Physicians are skeptical on PACIFIC: 8% of 13 verified physician voices positive, 15% nuanced (praising the result while flagging a caveat), 54% neutral, 23% critical.

15%

54%

23%

Positive 8% Nuanced 15% Neutral 54% Critical 23%

Denominator: 13 distinct verified physician voices across 19 oncologist posts, 2023-03-01 to 2024-05-05. Sponsor: AstraZeneca

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Primary sources: ClinicalTrials.gov · NCT02125461

Physician voices — verbatim

1/ finally, individualization of therapy in stage III #lungcancer at #ESTRO24 by Dr Ohri 🙏🙏🙏 #precisiononcology What happens after PACIFIC? Well local failure happens in larger tumors (for which 60-66 Gybis not enough)#radbio 🔥 @JoeChangMD @bslotman @CancerConnector

Henning Willers, MD

@HenningWillers

Something went very wrong with this trial. If you look at the 50% of pts treated in Europe they did similarly to PACIFIC for PFS and OS (despite being randomized pre-CRT), but those tx in Asia and S America did horribly. Differences in treatment standards? Experience with irAEs?… https://t.co/IlkIur50HT https://t.co/VQyAEBmFUw

Nathan A. Pennell MD, PhD, FASCO

@n8pennell